2-(2,5-difluoro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine | 479691-24-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(2,5-difluoro-benzyloxy)-4-(2(R)-methyl-piperazin-1-yl)-pyrimidine
• 英文别名: 2-[(2,5-difluorophenyl)methoxy]-4-[(2R)-2-methylpiperazin-1-yl]pyrimidine
• CAS: 479691-24-2
• 化学式: C₁₆H₁₈F₂N₄O
• 分子量: 320.342
• InChiKey: BQYVCCOLZOZOFW-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  50.3
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• 5-HT receptor ligands and uses thereof
  申请人：——

  公开号：US20030105106A1

  公开（公告）日：2003-06-05

  Compounds of Formula (IA) that act as 5-HT receptor ligands and their uses in the treatment of diseases linked to the activation of 5-HT 2 receptors in animals are described herein. 1

  本文描述了作为5-HT受体配体的化合物（IA）及其在治疗与动物5-HT2受体激活相关的疾病中的用途。
• Treatment of incontinence with 5htc2 agonists
  申请人：Pfizer Inc.

  公开号：EP2277513A2

  公开（公告）日：2011-01-26

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of stress urinary incontinence. The present invention also relates to a method of treatment of stress urinary incontinence, to assays to screen for compounds useful in the treatment of stress urinary incontinence, and to methods of preparing compositions for the treatment of stress urinary incontinence.

  本发明涉及使用5-HT2C受体激动剂治疗压力性尿失禁。本发明还涉及一种治疗压力性尿失禁的方法，涉及筛选用于治疗压力性尿失禁的化合物的检测方法，以及涉及制备治疗压力性尿失禁的组合物的方法。
• Treatment of incontinence
  申请人：Pfizer Inc

  公开号：US20040235856A1

  公开（公告）日：2004-11-25

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.

  本发明涉及使用 5-HT2C 受体的激动剂治疗尿失禁，最好是混合性尿失禁或压力性尿失禁。本发明还涉及使用 5-HT2C 受体拮抗剂治疗尿潴留。本发明还涉及一种治疗尿失禁的方法，涉及筛选治疗尿失禁有用化合物的检测方法，以及制备治疗尿失禁组合物的方法。
• 5-HT RECEPTOR LIGANDS AND USES THEREOF
  申请人：Pfizer Products Inc.

  公开号：EP1401819A1

  公开（公告）日：2004-03-31
• TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS
  申请人：Pfizer Limited

  公开号：EP1620081A2

  公开（公告）日：2006-02-01